Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WOEST-3
NL-OMON59959Phase 4Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib), atrial flutter (AFL), acute coronary syndrome (ACS) and 1 more (2 arms), sponsored by St. Antonius Ziekenhuis. Started Jan 2023; status: recruiting.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)acute coronary syndrome (ACS)Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NL-OMON59959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59959.